ELOA2

Summary

ELOA2 (elongin A2, HGNC:30771) is a protein-coding gene on chromosome 18q21.1, encoding Elongin-A2 (Q8IYF1). SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites.

This gene encodes the transcriptionally active subunit of the SIII (or elongin) transcription elongation factor complex, which also includes two regulatory subunits, elongins B and C. This complex acts to increase the rate of RNA chain elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites along the DNA template. Whereas a related protein with similar function, elongin A, is ubiquitously expressed, the encoded protein is specifically expressed in the testis, suggesting it may have a role in spermatogenesis.

Source: NCBI Gene 51224 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 233 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_016427

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30771
Approved symbol	ELOA2
Name	elongin A2
Location	18q21.1
Locus type	gene with protein product
Status	Approved
Aliases	HsT832, TCEB3L
Ensembl gene	ENSG00000206181
Ensembl biotype	protein_coding
OMIM	609522
Entrez	51224

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000332567

RefSeq mRNA: 1 — MANE Select: NM_016427 NM_016427

CCDS: CCDS11932

Canonical transcript exons

ENST00000332567 — 1 exons

Exon	Start	End
ENSE00001325424	47032527	47035621

Expression profiles

Bgee: expression breadth broad, 12 present calls, max score 92.03.

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.03	gold quality
sperm	CL:0000019	85.67	gold quality
male germ cell	CL:0000015	82.65	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	60.94	gold quality
pancreatic ductal cell	CL:0002079	60.37	silver quality
left testis	UBERON:0004533	58.85	gold quality
right testis	UBERON:0004534	58.51	gold quality
testis	UBERON:0000473	57.51	gold quality
triceps brachii	UBERON:0001509	57.50	gold quality
gluteal muscle	UBERON:0002000	56.88	gold quality
decidua	UBERON:0002450	56.55	gold quality
vena cava	UBERON:0004087	53.60	gold quality
myocardium	UBERON:0002349	53.40	gold quality
ileal mucosa	UBERON:0000331	52.72	silver quality
hair follicle	UBERON:0002073	52.43	gold quality
colonic epithelium	UBERON:0000397	49.88	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
quadriceps femoris	UBERON:0001377	48.96	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
deltoid	UBERON:0001476	48.84	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
vastus lateralis	UBERON:0001379	48.32	gold quality
bone marrow cell	CL:0002092	48.29	gold quality
left ventricle myocardium	UBERON:0006566	48.24	gold quality
orbitofrontal cortex	UBERON:0004167	48.20	gold quality
upper arm skin	UBERON:0004263	48.06	gold quality
cervix epithelium	UBERON:0004801	48.04	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting ELOA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-609	99.82	64.26	505
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-6733-3P	99.54	67.80	1281
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-2276-3P	98.76	67.75	1384
HSA-MIR-4680-3P	98.64	68.60	2093

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	eloa	ENSDARG00000102365
rattus_norvegicus	Eloa2l	ENSRNOG00000066342
rattus_norvegicus		ENSRNOG00000072061
rattus_norvegicus		ENSRNOG00000076010
rattus_norvegicus		ENSRNOG00000076585
rattus_norvegicus		ENSRNOG00000081139
drosophila_melanogaster	EloA	FBGN0039066
caenorhabditis_elegans		WBGENE00010990

Paralogs (1): ELOA (ENSG00000011007)

Protein

Protein identifiers

Elongin-A2 — Q8IYF1 (reviewed: Q8IYF1)

Alternative names: RNA polymerase II transcription factor SIII subunit A2, Transcription elongation factor B polypeptide 3B

All UniProt accessions (1): Q8IYF1

UniProt curated annotations — full annotation on UniProt →

Function. SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A2 is transcriptionally active but its transcription activity is not enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex).

Subunit / interactions. Heterotrimer of an A (ELOA, ELOA2 or ELOA3P), ELOB and ELOC subunit.

Subcellular location. Nucleus.

Tissue specificity. Specifically expressed in testis.

Domain organisation. The BC-box, which mediates binding to the elongin BC complex, has the consensus sequence [APST]-L-x(3)-C-x(3)-[AILV].

RefSeq proteins (1): NP_057511* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003617	TFIIS/CRSP70_N_sub	Domain
IPR010684	RNA_pol_II_trans_fac_SIII_A	Family
IPR017923	TFIIS_N	Domain
IPR035441	TFIIS/LEDGF_dom_sf	Homologous_superfamily
IPR051870	Elongin-A_domain	Family

Pfam: PF06881, PF08711

UniProt features (25 total): compositionally biased region 8, region of interest 7, sequence variant 5, sequence conflict 3, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IYF1-F1	54.67	0.09

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-112382	Formation of RNA Pol II elongation complex
R-HSA-167152	Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200	Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-167238	Pausing and recovery of Tat-mediated HIV elongation
R-HSA-167243	Tat-mediated HIV elongation arrest and recovery
R-HSA-167246	Tat-mediated elongation of the HIV-1 transcript
R-HSA-167287	HIV elongation arrest and recovery
R-HSA-167290	Pausing and recovery of HIV elongation
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes
R-HSA-75955	RNA Polymerase II Transcription Elongation

MSigDB gene sets: 48 (showing top): FOXO1_01, REACTOME_HIV_INFECTION, OCT1_06, IRF_Q6, PIT1_Q6, YNGTTNNNATT_UNKNOWN, WEBER_METHYLATED_ICP_IN_SPERM_DN, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOCC_TRANSCRIPTION_ELONGATION_FACTOR_COMPLEX, ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP, chr18q21, GOBP_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, MARTENS_TRETINOIN_RESPONSE_UP, ATM_DN.V1_DN, REACTOME_TRANSCRIPTION_OF_THE_HIV_GENOME

GO Biological Process (4): transcription by RNA polymerase II (GO:0006366), transcription elongation by RNA polymerase II (GO:0006368), regulation of DNA-templated transcription elongation (GO:0032784), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): nucleoplasm (GO:0005654), elongin complex (GO:0070449), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Transcription of the HIV genome	5
RNA Polymerase II Transcription	2
RNA Polymerase II Transcription Elongation	1
Tat-mediated elongation of the HIV-1 transcript	1
HIV Transcription Elongation	1
Transcriptional Regulation by TP53	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
DNA-templated transcription elongation	2
transcription by RNA polymerase II	1
regulation of DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
binding	1
nuclear lumen	1
cellular anatomical structure	1
transcription elongation factor complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1009 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELOA2	ELOC	Q15369	989
ELOA2	ELOB	Q15370	966
ELOA2	CUL5	Q93034	792
ELOA2	TCEA2	Q15560	716
ELOA2	VHL	P40337	715
ELOA2	TCEA1	P23193	707
ELOA2	TCEA3	O75764	706
ELOA2	REXO1	Q8N1G1	693
ELOA2	CUL2	Q13617	665
ELOA2	LRRC41	Q15345	629
ELOA2	MED26	O95402	626
ELOA2	SKIC8	Q9GZS3	617
ELOA2	LEO1	Q8WVC0	550
ELOA2	CDC73	Q6P1J9	543
ELOA2	RNF7	Q9UBF6	529

IntAct

48 interactions, top by confidence:

A	B	Type	Score
ZCCHC10	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ELOA2	ZCCHC10	psi-mi:“MI:0915”(physical association)	0.560
SREK1IP1	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
RNPS1	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ZNF138	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
NKAPD1	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
CHD2	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ELOA2	SREK1IP1	psi-mi:“MI:0915”(physical association)	0.560
VHL	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ZBTB43	ELOA2	psi-mi:“MI:0915”(physical association)	0.550
TRAF2	ELOA2	psi-mi:“MI:0915”(physical association)	0.550
DVL2	ELOA2	psi-mi:“MI:0915”(physical association)	0.550
CALCOCO2	ELOA2	psi-mi:“MI:0915”(physical association)	0.550
ELOA2	CDK6	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ZNF165	ELOA2	psi-mi:“MI:0915”(physical association)	0.370
TRIM37	ELOA2	psi-mi:“MI:0915”(physical association)	0.370
ELOA2	KXD1	psi-mi:“MI:0915”(physical association)	0.370
ELOA2	SOHLH2	psi-mi:“MI:0915”(physical association)	0.370
ELOA2	CEP70	psi-mi:“MI:0915”(physical association)	0.370
ELOA2	KRTAP4-12	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (63): ZCCHC10 (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), KXD1 (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), SOHLH2 (Two-hybrid), CEP70 (Two-hybrid), KRTAP4-12 (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid), TCEB3B (Two-hybrid)

ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0

Diamond homologs: Q09413, Q14241, Q63187, Q8CB77, Q8IYF1, Q9VCP0, F4J4Y5, P10711, P23193, Q29RL9, Q4KLL0, Q9FHK9, Q9ZVH8, O59671, Q75E67

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

233 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	193
Likely benign	33
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
545224	NC_000018.10:g.(?47026162)(47075742_?)del	Likely pathogenic

SpliceAI

114 predictions. Top by Δscore:

Variant	Effect	Δscore
18:47033559:C:CA	acceptor_gain	0.9300
18:47033971:G:GT	donor_gain	0.7900
18:47033783:TG:T	donor_gain	0.7800
18:47033757:A:T	donor_gain	0.7400
18:47033557:T:A	acceptor_gain	0.6900
18:47033557:TGCGA:T	acceptor_gain	0.6500
18:47033815:TCATG:T	donor_gain	0.6100
18:47035465:C:G	donor_gain	0.6100
18:47035332:G:GT	donor_gain	0.6000
18:47033704:C:T	donor_gain	0.5700
18:47033997:G:GT	donor_gain	0.5500
18:47033567:C:G	acceptor_gain	0.5400
18:47033975:C:T	donor_gain	0.5400
18:47033756:G:T	donor_gain	0.5000
18:47033566:GCT:G	acceptor_gain	0.4900
18:47033565:AGCT:A	acceptor_gain	0.4800
18:47033566:GCTG:G	acceptor_gain	0.4800
18:47034663:GCCGC:G	donor_gain	0.4800
18:47034105:AG:A	donor_gain	0.4700
18:47034106:GG:G	donor_gain	0.4700
18:47035556:TGCCA:T	donor_gain	0.4400
18:47035557:GCCAG:G	donor_gain	0.4400
18:47033874:TCCCA:T	donor_gain	0.4300
18:47033561:A:T	acceptor_gain	0.4200
18:47035568:GCCT:G	donor_gain	0.4100
18:47033811:G:T	donor_gain	0.4000
18:47033556:CTGCG:C	acceptor_gain	0.3800
18:47033565:A:AG	acceptor_gain	0.3800
18:47033566:G:GG	acceptor_gain	0.3800
18:47034357:C:G	donor_gain	0.3800

AlphaMissense

4907 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:47035173:A:G	L31S	0.982
18:47035048:A:G	W73R	0.979
18:47035048:A:T	W73R	0.979
18:47035068:G:T	A66D	0.968
18:47035046:C:A	W73C	0.965
18:47035046:C:G	W73C	0.965
18:47035047:C:G	W73S	0.955
18:47035164:A:T	L34H	0.949
18:47033024:C:A	K747N	0.946
18:47033024:C:G	K747N	0.946
18:47033042:C:A	K741N	0.933
18:47033042:C:G	K741N	0.933
18:47035119:A:G	I49T	0.929
18:47033015:G:C	F750L	0.928
18:47033015:G:T	F750L	0.928
18:47033017:A:G	F750L	0.928
18:47033048:C:A	M739I	0.927
18:47033048:C:G	M739I	0.927
18:47033048:C:T	M739I	0.927
18:47035224:A:G	L14P	0.926
18:47035098:A:G	L56P	0.923
18:47035164:A:G	L34P	0.919
18:47035107:A:T	V53E	0.913
18:47035212:A:G	L18P	0.912
18:47035059:A:G	L69S	0.903
18:47035077:C:T	G63D	0.900
18:47035212:A:T	L18Q	0.891
18:47035047:C:A	W73L	0.881
18:47035119:A:C	I49S	0.880
18:47035149:A:G	M39T	0.880

dbSNP variants (sampled 300 via entrez): RS1000950374 (18:47037436 G>A,T), RS1000954362 (18:47032658 A>G), RS1001006530 (18:47032376 A>G), RS1001901417 (18:47035279 G>A,T), RS1002554775 (18:47032134 G>T), RS1003490519 (18:47035503 A>C,G), RS1005001060 (18:47035324 C>A,G,T), RS1005180673 (18:47036291 G>T), RS1007258886 (18:47033609 G>A,C,T), RS1007457119 (18:47032825 G>A,T), RS1008347692 (18:47034879 C>T), RS1008357275 (18:47032868 C>A,G,T), RS1008845898 (18:47032191 C>G,T), RS1009128879 (18:47032039 A>G,T), RS1009711124 (18:47037009 A>C)

Disease associations

OMIM: gene MIM:609522 | disease phenotypes: MIM:181500

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), schizophrenia (MONDO:0005090)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010136_31	Fruit consumption	2.000000e-14

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008111	diet measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
terbufos	increases methylation	1
CGP 52608	affects binding, increases reaction	1
theaflavin-3,3’-digallate	affects expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression	1
Fonofos	increases methylation	1
Parathion	increases methylation	1
Rotenone	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer